Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease—results of the Immune Metabolic Associations in Psoriatic Arthritis study

OBJECTIVES: Studies have suggested phosphodiesterase 4 (PDE4) inhibition may be associated with weight loss and other cardiometabolic benefits. We evaluated the effect of the PDE4 inhibitor apremilast on body weight and composition, glucose homeostasis, lipid profiles and vascular function in psoria...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferguson, Lyn D, Cathcart, Susanne, Rimmer, Dominic, Semple, Gary, Brooksbank, Katriona, Paterson, Caron, Brown, Rosemary, Harvie, John, Gao, Xuan, Radjenovic, Aleksandra, Welsh, Paul, McInnes, Iain B, Sattar, Naveed, Siebert, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889283/
https://www.ncbi.nlm.nih.gov/pubmed/34097014
http://dx.doi.org/10.1093/rheumatology/keab474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889283/
https://www.ncbi.nlm.nih.gov/pubmed/34097014
http://dx.doi.org/10.1093/rheumatology/keab474

Ejemplares similares